Immunocore Holdings plc (6YG)
TG
Immunocore presents three-year overall survival data from the KIMMTRAK Phase 3 trial Data published in New England Journal of Medicine and presented as a late breaking abstract in mini oral...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 30.4 | 31.6 | 30.4 | 25 | 31.424 | DE |
4 | 2.2 | 7.80141843972 | 28.2 | 32.6 | 28.2 | 27 | 31.10421053 | DE |
12 | 0.6 | 2.01342281879 | 29.8 | 32.6 | 27.6 | 60 | 30.12480666 | DE |
26 | -16.2 | -34.7639484979 | 46.6 | 46.6 | 27.6 | 65 | 33.06125917 | DE |
52 | -17.6 | -36.6666666667 | 48 | 71 | 27.6 | 57 | 42.17295949 | DE |
156 | -22.1 | -42.0952380952 | 52.5 | 71 | 27.6 | 53 | 42.64137493 | DE |
260 | -22.1 | -42.0952380952 | 52.5 | 71 | 27.6 | 53 | 42.64137493 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.